12:00 AM
Jul 27, 2009
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Liposomal ciprofloxacin: Phase IIb start

This quarter, Aradigm will begin a double-blind, placebo-controlled, international Phase IIb trial to evaluate 100 mg or 150 mg inhaled liposomal ciprofloxacin given once daily for 4 weeks in...

Read the full 124 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >